Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.

Conclusions: Regorafenib in our clinical practice has equal efficacy to reported data from pivotal registration trials. Our data suggest that performance status is the most important prognostic factor in patients treated with regorafenib, suggesting a careful selection of patients.
PMID: 30728734 [PubMed]

Source: Clinical Colorectal Cancer - February 9, 2019 Category: Cancer & Oncology Authors: Aljubran A, Elshenawy MA, Kandil M, Zahir MN, Shaheen A, Gad A, Alshaer O, Alzahrani A, Eldali A, Bazarbashi S Tags: Clin Med Insights Oncol Source Type: research